Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial

E. Vellenga, W.L. van Putten, M.B. van 't Veer, J.M. Zijlstra-Baalbergen, W.E. Fibbe, M.H. van Oers, L.F. Verdonck, P.W. Wijermans, G.W. van Imhoff, P.J. Lugtenburg, P.C. Huijgens

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined/Unknown
Pages (from-to)537-543
Issue number2
Publication statusPublished - 2008

Cite this